Biohaven (BHVN) shares were up over 4% in recent trading on Wednesday after the company said its two drug candidates are near market and it is doing phase three testing for four other indications.
BHV-4157 for the treatment of spinocerebellar ataxia and BHV-2000 for spinal muscular atrophy are closer to the market stage, according to the company.
The company is evaluating BHV-4157 as a treatment for patients with obsessive-compulsive disorder in a phase three study.
Other late-stage candidates include BHV-7000 for focal and generalized epilepsies and BHV-8000 for Parkinson's disease, Biohaven said.
Price: 16.29, Change: +0.50, Percent Change: +3.17
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。